Phase IIb Study of Intranasal Glutathione in Parkinson's Disease.

Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM

Journal of Parkinson's disease1 Jan 2017Cited by 78 (Europe PMC)

PMID28436395PMCIDPMC5438472DOI10.3233/jpd-161040PepBankPUB-28436395

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, high-dose GSH improved total UPDRS from baseline, with improvement also present in placebo.
In plain wordsIn Parkinson's disease, high-dose GSH improved total symptom scores from baseline, but placebo also improved.
Peptide
Glutathione
Outcome
DecreaseTotal UPDRS change
Study
n: not reported in source
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
200 mg thrice daily · intranasal · three monthsAs given in this study (human).
Measurements
Total UPDRS change
−4.6 points
High-dose group versus baseline
Total UPDRS change parenthetical value (statistic unspecified)
4.7 not stated
High-dose GSH group versus baseline; parenthetical statistic type is not stated
P value for Total UPDRS change
0.0025 unitless
High-dose GSH group versus baseline over the intervention period
Source sentences
Summary
The high-dose group demonstrated improvement in total Unified PD Rating Scale (UPDRS) (-4.6 (4.7), P = 0.0025) and UPDRS motor subscore (-2.2 (3.8), P = 0.0485) over baseline, although neither treatment group was superior to placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
All cohorts improved over the intervention period, including placebo.
Summary · context
This was a double-blind, placebo-controlled trial of 45 individuals with Hoehn & Yahr Stage 1-3 PD.
Summary · context
Participants were randomized to receive intranasal placebo (saline), 100 mg GSH, or 200 mg GSH thrice daily for three months, and were observed over a one-month washout period.
Report a problemFND-2843639501
02HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, high-dose GSH improved the UPDRS motor subscore from baseline, with improvement also present in placebo.
In plain wordsIn Parkinson's disease, high-dose GSH improved movement scores from baseline, but placebo also improved.
Peptide
Glutathione
Outcome
DecreaseUPDRS motor subscore change
Study
n: not reported in source
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
200 mg thrice daily · intranasal · three monthsAs given in this study (human).
Measurements
UPDRS motor subscore change
−2.2 points
High-dose group versus baseline
UPDRS motor subscore change parenthetical value (statistic unspecified)
3.8 not stated
High-dose GSH group versus baseline; parenthetical statistic type is not stated
P value for UPDRS motor subscore change
0.0485 unitless
High-dose GSH group versus baseline over the intervention period
Source sentences
Summary
The high-dose group demonstrated improvement in total Unified PD Rating Scale (UPDRS) (-4.6 (4.7), P = 0.0025) and UPDRS motor subscore (-2.2 (3.8), P = 0.0485) over baseline, although neither treatment group was superior to placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
All cohorts improved over the intervention period, including placebo.
Summary · context
This was a double-blind, placebo-controlled trial of 45 individuals with Hoehn & Yahr Stage 1-3 PD.
Summary · context
Participants were randomized to receive intranasal placebo (saline), 100 mg GSH, or 200 mg GSH thrice daily for three months, and were observed over a one-month washout period.
Report a problemFND-2843639502
03HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, low-dose GSH was not superior to placebo for total UPDRS.
In plain wordsIn Parkinson's disease, low-dose GSH did not improve total symptom scores more than placebo.
Peptide
Glutathione
Outcome
No significant changeTotal UPDRS versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
100 mg thrice daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
The high-dose group demonstrated improvement in total Unified PD Rating Scale (UPDRS) (-4.6 (4.7), P = 0.0025) and UPDRS motor subscore (-2.2 (3.8), P = 0.0485) over baseline, although neither treatment group was superior to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, placebo-controlled trial of 45 individuals with Hoehn & Yahr Stage 1-3 PD.
Summary · context
Participants were randomized to receive intranasal placebo (saline), 100 mg GSH, or 200 mg GSH thrice daily for three months, and were observed over a one-month washout period.
Report a problemFND-2843639503
04HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, low-dose GSH was not superior to placebo for the motor subscore.
In plain wordsIn Parkinson's disease, low-dose GSH did not improve movement scores more than placebo.
Peptide
Glutathione
Outcome
No significant changeMotor UPDRS versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
100 mg thrice daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
The high-dose group demonstrated improvement in total Unified PD Rating Scale (UPDRS) (-4.6 (4.7), P = 0.0025) and UPDRS motor subscore (-2.2 (3.8), P = 0.0485) over baseline, although neither treatment group was superior to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, placebo-controlled trial of 45 individuals with Hoehn & Yahr Stage 1-3 PD.
Summary · context
Participants were randomized to receive intranasal placebo (saline), 100 mg GSH, or 200 mg GSH thrice daily for three months, and were observed over a one-month washout period.
Report a problemFND-2843639504
05HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, high-dose GSH was not superior to placebo for total UPDRS.
In plain wordsIn Parkinson's disease, high-dose GSH did not improve total symptom scores more than placebo.
Peptide
Glutathione
Outcome
No significant changeTotal UPDRS versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
200 mg thrice daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
The high-dose group demonstrated improvement in total Unified PD Rating Scale (UPDRS) (-4.6 (4.7), P = 0.0025) and UPDRS motor subscore (-2.2 (3.8), P = 0.0485) over baseline, although neither treatment group was superior to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, placebo-controlled trial of 45 individuals with Hoehn & Yahr Stage 1-3 PD.
Summary · context
Participants were randomized to receive intranasal placebo (saline), 100 mg GSH, or 200 mg GSH thrice daily for three months, and were observed over a one-month washout period.
Report a problemFND-2843639505
06HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, high-dose GSH was not superior to placebo for the motor subscore.
In plain wordsIn Parkinson's disease, high-dose GSH did not improve movement scores more than placebo.
Peptide
Glutathione
Outcome
No significant changeMotor UPDRS versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
200 mg thrice daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
The high-dose group demonstrated improvement in total Unified PD Rating Scale (UPDRS) (-4.6 (4.7), P = 0.0025) and UPDRS motor subscore (-2.2 (3.8), P = 0.0485) over baseline, although neither treatment group was superior to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, placebo-controlled trial of 45 individuals with Hoehn & Yahr Stage 1-3 PD.
Summary · context
Participants were randomized to receive intranasal placebo (saline), 100 mg GSH, or 200 mg GSH thrice daily for three months, and were observed over a one-month washout period.
Report a problemFND-2843639506
07HumanRandomized controlled trialSafety outcome
In Parkinson's disease, one participant receiving high-dose GSH developed cardiomyopathy.
In plain wordsIn Parkinson's disease, one participant receiving high-dose GSH developed heart muscle disease.
Peptide
Glutathione
Outcome
Not applicableCardiomyopathy
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Studied dose
200 mg thrice daily · intranasal · three monthsAs given in this study (human).
Measurements
Cardiomyopathy events
1 participant
High-dose GSH cohort
Source sentences
Summary
One participant in the high-dose GSH cohort developed cardiomyopathy.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, placebo-controlled trial of 45 individuals with Hoehn & Yahr Stage 1-3 PD.
Summary · context
Participants were randomized to receive intranasal placebo (saline), 100 mg GSH, or 200 mg GSH thrice daily for three months, and were observed over a one-month washout period.
Report a problemFND-2843639507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords